Valneva SE (VALN) Assets Average (2022 - 2026)
Valneva SE's (VALN) quarterly Assets Average came in at $449.9 million in Q1 2026, down 13.61% year-on-year from $520.8 million in Q1 2025, and down 8.95% quarter-over-quarter from $494.1 million in Q4 2025.
Valneva SE (VALN) Assets Average (2022 - 2026) Analysis & Trends
Valneva SE has disclosed Assets Average across 5 years of filings, most recently posting $449.9 million for Q1 2026.
- Assets Average for Q1 2026 came in at $449.9 million, down 13.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $449.9 million (down 13.61% YoY), and the FY2025 annual result was $499.3 million, down 2.99% from the prior year.
- Assets Average came in at $449.9 million for Q1 2026 at Valneva SE, down from $494.1 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $903.9 million in Q1 2022 to a low of $449.9 million in Q1 2026.
- The 5-year median for Assets Average is $534.9 million (2024), against an average of $596.3 million.
- Across the five-year window, Assets Average declined 29.91% in 2023 and rose 3.77% in 2024, its largest moves.
- Valneva SE's Assets Average stood at $668.9 million in 2022, then retreated by 20.64% to $530.8 million in 2023, then increased by 3.77% to $550.8 million in 2024, then declined by 10.3% to $494.1 million in 2025, then decreased by 8.95% to $449.9 million in 2026.
- The last three Assets Average figures came in at $449.9 million (Q1 2026), $494.1 million (Q4 2025), and $529.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 33.42 Mn |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | 795.91 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 13.04 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 1.72 Bn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 40.89 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | 26.03 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 10.06 Mn |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 26.06 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 660.38 Mn |
| 10 | Valneva SE | 167.33 Mn | 44.10 Mn | 5.08 Mn | 449.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 449.90 Mn |
| Dec 31, 2025 | 494.13 Mn |
| Sep 30, 2025 | 529.50 Mn |
| Jun 30, 2025 | 521.13 Mn |
| Mar 31, 2025 | 520.80 Mn |
| Dec 31, 2024 | 550.84 Mn |
| Sep 30, 2024 | 534.90 Mn |
| Jun 30, 2024 | 524.35 Mn |
| Mar 31, 2024 | 520.63 Mn |
| Dec 31, 2023 | 530.83 Mn |
| Sep 30, 2023 | 578.74 Mn |
| Jun 30, 2023 | 612.05 Mn |
| Mar 31, 2023 | 633.60 Mn |
| Dec 31, 2022 | 668.89 Mn |
| Sep 30, 2022 | 738.79 Mn |
| Jun 30, 2022 | 823.29 Mn |
| Mar 31, 2022 | 903.94 Mn |